On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer ...
Genomics is collaborating with PharosAI and leading UK institutions to build a large multimodal cancer dataset using its ...
The biotechnology services provider expanded its offerings with advanced gene expression analysis technology for research ...
Genomics (NASDAQ:TXG) reported fourth-quarter revenue of $166 million, surpassing the high end of its guidance range, as ...
Since the launch of the Hong Kong laboratory in July 2025, Omics Empower has supported research teams with local single-cell sequencing and spatial transcriptomics services. Faster processing helps ...
10x Genomics’ earnings call highlighted a business leaning on consumables strength and innovation to offset a harsh capital spending backdrop. For investors, the story is one of prudent financial ...
Genomics Inc (TXG) reports strong consumables growth and a robust cash position, despite challenges in instrument revenue and research funding dynamics.
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel precision medicine PharosAI brings together King's College London, ...
Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for ...
PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results